泛癌分析揭示铁死亡相关基因的预后价值及性别特异性关联
本研究通过文献综述与FerrDb数据库交叉筛选出55个铁死亡相关基因,在五种常接受放疗的癌症中评估其表达与总生存(OS)的关联,并分析生物性别及放疗预后的关系。结果显示18–35个基因与OS显著相关,GLS2和BECN1在全部五种癌症中与OS改善相关,SLC7A11在四种癌症中显著且多与较差OS相关,并检测到三个基因与OS关联的性别差异。在65例接受放疗的肺癌患者中,HSPB1、GLS2和GPX4与OS改善相关,SLC7A11与OS较差相关。
要点
- 55个铁死亡相关基因中18–35个与五种癌症OS显著相关。
- GLS2和BECN1在五种癌症中均与OS改善相关。
- SLC7A11在四种癌症中显著且多与较差OS相关。
核心结论
- 首次提供铁死亡相关基因表达存在性别差异且具潜在临床相关性的证据。
- SLC7A11、BECN1和GLS2被列为未来机制与临床研究的高优先级候选基因。
研究设计与样本
- 通过文献综述与FerrDb数据库交叉筛选出55个候选铁死亡调节基因。
- 选取五种常接受放疗的癌症进行Kaplan-Meier分析评估各基因与OS的关联,记录HR和p值。
- 对候选基因按生物性别进行分层分析,并在65例接受放疗的肺癌患者队列中重复分析。
主要发现
- 在五种癌症中,55个铁死亡相关基因中有18–35个与OS显著相关。
- GLS2和BECN1在全部五种癌症中与OS改善显著相关。
- SLC7A11在四种癌症中显著且通常与较差OS相关。
- 检测到GLS2、BECN1和SLC7A11与OS关联的性别差异。
- 在65例接受放疗的肺癌患者中,HSPB1、GLS2和GPX4与OS改善相关,SLC7A11与OS较差相关。
关键数值与推荐
- 五种癌症中55个铁死亡相关基因有18–35个与OS显著相关。
- 放疗肺癌患者队列样本量为65例。
- GLS2和BECN1在五种癌症中均与OS改善显著相关。
- SLC7A11在四种癌症中显著且多与较差OS相关。
临床怎么用
- 可将SLC7A11、BECN1和GLS2作为未来机制与临床研究的高优先级候选基因。
- 在研究设计与结果解读中纳入性别作为生物学变量以提升临床相关性。
- 在放疗肺癌患者中可关注HSPB1、GLS2、GPX4和SLC7A11与OS的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate the association of ferroptosis-related gene expression with overall survival (OS) across multiple cancer types and explore their relationship to biological sex and radiation therapy (RT) outcomes. METHODS: Ferroptosis regulators were identified through a literature review and cross-referenced with the FerrDb database, yielding 55 candidate genes. Five cancers commonly treated with RT were selected. Kaplan-Meier analyses were performed to assess OS associations for each gene, with hazard ratios (HR) and p-values recorded. Segregated analysis according to biological sex were conducted on candidate genes. The analysis was repeated in a cohort of RT treated lung cancer patients. RESULTS: Across five cancers commonly treated with radiation therapy (RT), 18-35 of 55 ferroptosis-related genes were significantly associated with overall survival (OS). GLS2 and BECN1 were significantly associated with improved OS in all five cancers. SLC7A11 was significant in four cancers and generally associated with poorer OS. Sex differences in the association between these three genes and OS were detected. In RT-treated lung cancer patients (n = 65), HSPB1, GLS2 and GPX4 were associated with improved OS, SLC7A11 with worse OS. CONCLUSIONS: This study provides first evidence of sex-differences in ferroptosis-related gene expression with potential clinical relevance. This pan-cancer resource links ferroptosis-related genes to survival outcomes and highlights SLC7A11, BECN1, and GLS2 as high-priority candidates for future mechanistic and clinical studies. Integrating sex as a biological variable into study design and interpretation will enhance clinical relevance.
引用
- Samuel M, Marignol L. Pan-Cancer profiling of ferroptosis-related genes reveals prognostic biomarkers and sex-specific associations. Clin Transl Radiat Oncol. 2025. PMID: 41492406. doi:10.1016/j.ctro.2025.101095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。